Detected ·
Vaderis Therapeutics AG
$152M—
Vaderis Therapeutics AG has raised $152M in an oversubscribed Series B round led by TCGX Life Sciences and Omega Funds, with participation from Perceptive Advisors, Medicxi, and others. The Swiss biotech develops gene therapies targeting rare neurological disorders and will use the funds to advance its lead program into pivotal clinical trials.
- Website
- —
- Amount
- $152 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-14 04:06:18 UTC
- Signal ID
- 7ff737be-2e49-470c-817d-75464c3b3e1a
As the API returns it
{
"id": "7ff737be-2e49-470c-817d-75464c3b3e1a",
"created_at": "2026-08-14T04:06:18.247096Z",
"company_name": "Vaderis Therapeutics AG",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/vaderis-therapeutics-ag",
"event_type": "funding",
"funding_amount": 152000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Vaderis Therapeutics AG has raised $152M in an oversubscribed Series B round led by TCGX Life Sciences and Omega Funds, with participation from Perceptive Advisors, Medicxi, and others. The Swiss biotech develops gene therapies targeting rare neurological disorders and will use the funds to advance its lead program into pivotal clinical trials.*"
}